Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
RXRX filed a Form 144 reporting an insider sale notice for Class A common stock. The filing lists a proposed sale tied to
Recursion Pharmaceuticals, Inc. reported new equity awards to its CEO and President, Najat Khan. On February 6, 2026, Khan received 1,673,546 shares of Class A common stock for no cash cost through restricted stock units. An additional 30,346 RSU-based shares vested immediately on the grant date.
The large RSU grant vests in equal sixteenth portions, starting May 15, 2026 and then every three months. To cover taxes on these equity awards, 10,364 shares were withheld at a price of $3.98 per share. After these transactions, Khan directly owned 2,304,663 Class A common shares.
Recursion Pharmaceuticals’ Chief Financial Officer Ben R. Taylor reported equity compensation activity. On February 6, 2026, he received 446,279 Class A RSUs that vest in equal sixteenth installments starting May 15, 2026 and every three months afterward, plus 24,254 RSUs that vested immediately.
The company also withheld 11,400 shares at $3.98 per share to satisfy tax obligations from RSU settlement. After these transactions, Taylor directly beneficially owned 1,220,683 shares of Class A Common Stock.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported equity compensation transactions in Class A common stock. On February 6, 2026, he acquired 502,064 shares at $0 per share from a restricted stock unit (RSU) grant that vests in sixteenth installments starting May 15, 2026 and every three months thereafter. He also acquired 24,254 shares at $0 per share from an RSU that vested immediately on the grant date. On the same day, 11,400 shares were withheld at $3.98 per share to cover tax obligations related to RSU settlement. After these transactions, Hallett directly owned 1,109,059 Class A shares.
Recursion Pharmaceuticals director Christopher Gibson reported several stock transactions in early February 2026. On February 4, he converted 40,000 shares of Class B Common Stock into Class A at $0 per share, then sold 40,000 Class A shares at $4.12 under a pre-arranged Rule 10b5-1 trading plan.
On February 6, Gibson received 30,346 Class A shares from restricted stock units that vested immediately at $0, and 10,364 shares were withheld at $3.56 to cover taxes. After these transactions, he directly held 933,821 Class A shares, alongside sizable option and convertible Class B positions.
Recursion Pharmaceuticals director Blake Borgeson sold 220,000 shares of Class A common stock on February 3, 2026 at $4.20 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 31, 2025. After this transaction, he beneficially owned 6,429,863 shares, held directly.
Baillie Gifford & Co reports beneficial ownership of 23,774,972 shares of Recursion Pharmaceuticals, Inc. Class A common stock, representing 4.62% of the class as of December 31, 2025. The firm has sole voting power over 23,730,293 shares and sole dispositive power over all 23,774,972 shares.
The filer identifies itself as an investment adviser and states the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Recursion. The filing confirms ownership has fallen to 5 percent or less of the class.
A holder of Class A shares has filed a notice to sell 40,000 shares through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $164,800.00. The shares were originally acquired on 09/01/2016 as founders’ shares from the issuer as compensation.
Over the prior three months, the same seller, identified as Christopher C. Gibson, reported six separate sales of 40,000 Class A shares each, between 11/04/2025 and 01/20/2026, at disclosed gross proceeds ranging from $166,400.00 to $208,400.00. By signing, the seller represents they do not know of undisclosed material adverse information about the issuer.
Recursion Pharmaceuticals, Inc. shareholder ARK Investment Management LLC and its founder Catherine D. Wood have updated their ownership disclosure. They report beneficial ownership of 37,316,856 shares of Class A common stock, representing 7.25% of the class as of the event date.
ARK has sole voting power over 35,278,842 shares and shared voting power over 592,161 shares, with sole dispositive power over all 37,316,856 shares. Catherine D. Wood reports shared voting power over 35,871,003 shares and shared dispositive power over 37,316,856 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Recursion.
This Form 144 notice shows Blake C. Borgeson planning to sell up to 220,000 shares of the issuer’s Class A stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $924,000.
The filing also describes how these securities were acquired as founder shares from the issuer in two compensation grants of 110,000 Class A shares each on 09/01/2016 and 09/01/2017.
Over the past three months, Borgeson has already sold 220,000 Class A shares on 12/02/2025 for gross proceeds of $961,400 and another 220,000 shares on 01/06/2026 for $959,200.